TY - JOUR
KW - antidepressant effects attenuation
KW - Ketamine
KW - opioid receptor antagonism
KW - treatment-resistant depression
KW - antidepressant effects
KW - dissociative effects
KW - Naltrexone
KW - Neural Receptors
KW - Drug Therapy
KW - Antidepressant Drugs
KW - Opiates
KW - Dissociation
KW - treatment resistant depression
KW - article
KW - 3340:Clinical Psychopharmacology
AU - Boris D. Heifets
AU - Nolan R. Williams
AU - Christine Blasey
AU - Keith Sudheimer
AU - Carolyn I. Rodriguez
AU - Alan F. Schatzberg
A1 - 
AD - Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University, Stanford, CA, US bheifets@stanford.edu; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, US nolanw@stanford.edu; Heifets, Boris D.,bheifets@stanford.edu
BT - The American Journal of Psychiatry
C5 - Healthcare Disparities; Opioids & Substance Use
CP - 3
DO - 10.1176/appi.ajp.2018.18111231r
IS - 3
JF - The American Journal of Psychiatry
LA - English
M1 - Journal Article
PB - American Psychiatric Assn
PY - 2019
SN - 0002-953X, 0002-953X
SP - 251
EP - 252
EP - 
T1 - Target population, dose, and timing considerations for understanding naltrexone’s subjective effect: Response to Amiaz
T2 - The American Journal of Psychiatry
TI - Target population, dose, and timing considerations for understanding naltrexone’s subjective effect: Response to Amiaz
U1 - Healthcare Disparities; Opioids & Substance Use
U3 - 10.1176/appi.ajp.2018.18111231r
VL - 176
VO - 0002-953X, 0002-953X
Y1 - 2019
Y2 - Mar 01
ER -